Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)

CAPS Rating: 2 out of 5

A development-stage pharmaceutical company focused on the acquisition, development and commercialization of prescription drugs for the treatment of drug addiction.

Recs

2
Player Avatar zzlangerhans (99.78) Submitted: 2/12/2013 2:39:09 AM : Outperform Start Price: $0.50 CPRX Score: +66.58

Let's see if I can catch a little bit of air with Catalyst, now that they've formally discontinued development of CPP-109 for addiction. That leaves them with CPP-109 for Tourette's and CPP-115 for infantile spasms and not a whole lot of cash. They also have that weird development agreement with Biomarin on Firdapse that gives me a headache every time I try to figure it out. The enterprise value of 6M does seem low, but of course it could be higher after the company reports their quarterly cash burn in March. Hopefully I'll be able to get 10-20 points out of this before things start to look sour again.

Featured Broker Partners


Advertisement